ClinicalTrials.gg
CompletedNCT05483166Updated Oct 29, 2026

Engaging Parents in Neuropsychological Rehabilitation for Childhood Cancer Survivors: The ImPACT Program - A Pilot Study

An interventional study of ImPACT in Pediatric Cancer and Cognitive Dysfunction, sponsored by Aarhus University Hospital. Completed at 1 site in Denmark. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Aarhus University Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
10 Years to 17 Years
Sex
All
01

Study summary

The aim of the present pilot study is to evaluate the feasibility, acceptability, and preliminary efficacy of a novel, context-sensitive neuropsychological rehabilitation intervention for childhood cancer survivors and their families.

Read the detailed description

Cognitive impairment is the most common late effect in childhood cancer survivors, and despite the negative effects of these symptoms on quality of life, scholastic achievement and long-term socioeconomic outcomes, there continues to be no "gold standard" treatment for childhood cancer survivors with cognitive impairment.

Indeed, there is a dearth of research on interventions to treat cognitive impairment in childhood cancer survivors, and the relatively few studied interventions have proven limited effects. Arguably, four key elements are missing from a majority of studied interventions:1) transfer of learning to real-world functional outcomes, 2) awareness training to enhance compensatory strategy use, 3) inclusion of parents that could enhance transfer of learning to the home, and 4) recognition of the inter-related nature of cognitive, neurobehavioral, and psychological functions.

The "I'M aware: Parents and Children Together (ImPACT)" program is a novel, context-sensitive neuropsychological rehabilitation intervention that targets the above mentioned missing elements in previous rehabilitation efforts. The present pilot study aims to assess the feasibility, acceptability, and preliminary efficacy of this program in childhood cancer survivors with cognitive impairment in preparation for a large-scale randomized controlled trial.

02

Conditions studied

  • Pediatric Cancer
  • Cognitive Dysfunction

Keywords

  • Pediatric Cancer
  • Cognitive Dysfunction
  • Neuropsychological Rehabilitation
  • Neurobehavioral Impairment
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 10 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Aarhus University Hospital is the lead sponsor of 298 studies on the registry; 80 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cancer diagnosis of a leukemia, lymphoma, or central nervous system tumor
  • Completed primary treatment at least 6 months ago
  • Not terminally ill
  • Attend school
  • Living with one or more parents who speak Danish and are willing to co-participate
  • Screened as having parent-reported cognitive and/or neurobehavioral impairment

Exclusion criteria

Exclusion Criteria:

  • Confounding diagnosed or suspected psychiatric or medical condition unrelated to the cancer or its treatment that might contribute to cognitive or neurobehavioral impairment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    ImPACT program

    The ImPACT program consists of 8 weekly 1-hour sessions with homework between sessions.

    Behavioral: ImPACT

Interventions

  • BehavioralImPACT

    During the ImPACT program, the childhood cancer survivor and at least one parent collaborates on: 1. Becoming aware of the child's core strengths and difficulties 2. Helping the child to be optimally responsive to the guidance of the parent(s), and 3. Creating compensatory strategies to respond to real-world manifestations of the child's difficulties and helping the child implement these strategies at home.

06

What researchers measure

Primary outcomes

  1. Parent-reported neurobehavioral functioning

    The parent-report screening version of the Behavior Rating Inventory of Executive Function 2nd Edition (BRIEF-2). 12 items: answer format range: 1-3; total score range: 12-36. Higher score indicates more impairment.

    Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)

  2. Parent-reported cognitive functioning

    The parent-report version of the Pediatric Perceived Cognitive Function (PedsPCF) Short Form. 7 items: answer format range 1-5; total score range: 7-35. Lower score indicates more impairment.

    Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)

Secondary outcomes

  1. Parent-reported neurobehavioral functioning

    The parent-report version of the Behavior Rating Inventory of Executive Function 2nd Edition (BRIEF-2). 63 items: answer format range: 1-3; total score range: 63-189. Higher score indicates more impairment.

    Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)

  2. Parent-reported cognitive functioning

    The parent-report version of the Pediatric Perceived Cognitive Function (PedsPCF) Short Form. 7 items: answer format range 1-5; total score range: 7-35. Lower score indicates more impairment.

    Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)

  3. Child-reported neurobehavioral functioning

    The child-report version of the Behavior Rating Inventory of Executive Function 2nd Edition (BRIEF-2). 55 items: answer format range: 1-3; total score range: 55-165. Higher score indicates more impairment.

    Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)

  4. Child-reported neurobehavioral functioning

    The child-report version of the Behavior Rating Inventory of Executive Function 2nd Edition (BRIEF-2). 55 items: answer format range: 1-3; total score range: 55-165. Higher score indicates more impairment.

    Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)

  5. Child-reported cognitive functioning

    The child-report version of the Pediatric Perceived Cognitive Function (PedsPCF) Short Form. 7 items: answer format range 1-5; total score range: 7-35. Lower score indicates more impairment.

    Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)

  6. Child-reported cognitive functioning

    The child-report version of the Pediatric Perceived Cognitive Function (PedsPCF) Short Form. 7 items: answer format range 1-5; total score range: 7-35. Lower score indicates more impairment.

    Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)

  7. Parent-reported pediatric quality of life

    The parent-report version of the Pediatric Quality of Life (PedsQL) Core and Cancer scale. 23 items for the Core Scale, 25 items for the Cancer Scale: answer format range: 0-4; total score range: 0-100 (both scales). Lower scores indicate more impairment.

    Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)

  8. Parent-reported pediatric quality of life

    The parent-report version of the Pediatric Quality of Life Inventory (PedsQL) Core and Cancer scale. 23 items for the Core Scale, 25 items for the Cancer Scale: answer format range: 0-4; total score range: 0-100 (both scales). Lower scores indicate lower quality of life.

    Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)

  9. Child-reported pediatric quality of life

    The child-report version of the Pediatric Quality of Life (PedsQL) Core and Cancer scale. 23 items for the Core Scale, 25 items for the Cancer Scale: answer format range: 0-4; total score range: 0-100 (both scales). Lower scores indicate more impairment.

    Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)

  10. Child-reported pediatric quality of life

    The child-report version of the Pediatric Quality of Life (PedsQL) Core and Cancer scale. 23 items for the Core Scale, 25 items for the Cancer Scale: answer format range: 0-4; total score range: 0-100 (both scales). Lower scores indicate more impairment.

    Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)

  11. Parent-reported pediatric anxiety and depression

    The parent-report version of the Revised Children's Anxiety and Depression Scale (CADS) Short Form. 47 items: answer format range: 0-3; total score range: 0-27 (social phobia and panic disorder subscales), 0-30 (major depressive disorder subscale), 0-21 (social anxiety disorder subscale), 0-18 (generalized anxiety disorder and obsessive compulsive disorder subscales). Higher scores indicate more anxiety and depression.

    Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)

  12. Parent-reported pediatric anxiety and depression

    The parent-report version of the Revised Children's Anxiety and Depression Scale (CADS) Short Form. 47 items: answer format range: 0-3; total score range: 0-27 (social phobia and panic disorder subscales), 0-30 (major depressive disorder subscale), 0-21 (social anxiety disorder subscale), 0-18 (generalized anxiety disorder and obsessive compulsive disorder subscales). Higher scores indicate more anxiety and depression.

    Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)

  13. Child-reported pediatric anxiety and depression

    The child-report version of the Revised Children's Anxiety and Depression Scale (CADS) Short Form. 47 items: answer format range: 0-3; total score range: 0-27 (social phobia and panic disorder subscales), 0-30 (major depressive disorder subscale), 0-21 (social anxiety disorder subscale), 0-18 (generalized anxiety disorder and obsessive compulsive disorder subscales). Higher scores indicate more anxiety and depression.

    Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)

  14. Child-reported pediatric anxiety and depression

    The child-report version of the Revised Children's Anxiety and Depression Scale (CADS) Short Form. 47 items: answer format range: 0-3; total score range: 0-27 (social phobia and panic disorder subscales), 0-30 (major depressive disorder subscale), 0-21 (social anxiety disorder subscale), 0-18 (generalized anxiety disorder and obsessive compulsive disorder subscales). Higher scores indicate more anxiety and depression.

    Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)

  15. Parent-reported pediatric fatigue

    The parent-report version of the Pediatric Quality of Life - Multidimensional Fatigue Scale (PedsQL-MFS). 18 items: answer format range 0-4; total score range: 0-100. Lower score indicates more fatigue.

    Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)

  16. Parent-reported pediatric fatigue

    The parent-report version of the Pediatric Quality of Life - Multidimensional Fatigue Scale (PedsQL-MFS). 18 items: answer format range 0-4; total score range: 0-100. Lower score indicates more fatigue.

    Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)

  17. Child-reported pediatric fatigue

    The child-report version of the Pediatric Quality of Life - Multidimensional Fatigue Scale (PedsQL-MFS). 18 items: answer format range 0-4; total score range: 0-100. Lower score indicates more fatigue.

    Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)

  18. Child-reported pediatric fatigue

    The child-report version of the Pediatric Quality of Life - Multidimensional Fatigue Scale (PedsQL-MFS). 18 items: answer format range 0-4; total score range: 0-100. Lower score indicates more fatigue.

    Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)

  19. Parent sense of competence

    The Parenting Sense of Competence Scale (PSC scale).17 items: answer format range 1-6; total score range: 16-102. Higher score indicates more competence.

    Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)

  20. Parent sense of competence

    The Parenting Sense of Competence Scale (PSC scale). 17 items: answer format range 1-6; total score range: 16-102. Higher score indicates more competence.

    Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)

  21. Parent-reported participant motivation

    The 7-item interest/enjoyment subscale of the Intrinsic Motivation Inventory (IMI). 7 items: answer format range 1-7; total score range: 1-7. Higher score indicates more motivation.

    Time frame: After last session (approximately 9 weeks after Baseline assessment (T1): Post-intervention, T3)

  22. Child-reported participant motivation

    The 7-item interest/enjoyment subscale of the Intrinsic Motivation Inventory (IMI). 7 items: answer format range 1-7; total score range: 1-7. Higher score indicates more motivation.

    Time frame: After last session (approximately 9 weeks after Baseline assessment (T1): Post-intervention, T3))

  23. Parent-reported participant satisfaction

    The Client Satisfaction Questionnaire (CSQ-8). 8 items: answer format range 1-4; total score range: 8-32. Higher score indicates better satisfaction.

    Time frame: After last session (approximately 9 weeks after Baseline assessment (T1): Post-intervention, T3)

  24. Child-reported participant satisfaction

    The Client Satisfaction Questionnaire (CSQ-8). 8 items: answer format range 1-4; total score range: 8-32. Higher score indicates better satisfaction.

    Time frame: After last session (approximately 9 weeks after Baseline assessment (T1): Post-intervention, T3)

  25. Objective cognitive functioning (Child only)

    Standard neuropsychological test battery. Different scoring formats.

    Time frame: Baseline (T1) to after last session (approximately 9 weeks later: Post-intervention, T3)

  26. Objective cognitive functioning (Child only)

    Standard neuropsychological test battery. Different scoring formats.

    Time frame: Baseline (T1) to 9 week after post-intervention (approximately 18 weeks later: Follow-up, T4)

Other outcomes

  1. Qualitative Interviews

    Following the T4 assessment, the child and parent(s) will be invited to participate in a 30-minutes semi-structured, audio recorded interview.

    Time frame: 9 week after post-intervention (approximately 18 weeks after Baseline assessment (T1): Follow-up, T4)

07

Study locations

1 site
  • Aarhus University
    Aarhus, 8000, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Jun 2026, 44 months.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 44 months is above that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Jun 2025 → Jun 2026 and completion Dec 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2022
First posted
Aug 1, 2022
StartActual
Oct 1, 2022
Primary completionActual
Jun 26, 2026was Jun 2025
CompletionActual
Jun 26, 2026was Dec 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 29, 2026
Primary completion
Jun 1, 2025→Jun 26, 2026 (actual)
Oct 29, 2026
Study completion
Dec 1, 2026→Jun 26, 2026 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Completed
    Primary completion Jun 1, 2025→Jun 26, 2026 (now actual)
    Study completion Dec 1, 2026→Jun 26, 2026 (now actual)
    + 3 other changes: contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05483166
Responsible party
Lisa Maria Wu (Associate Professor, University of Aarhus) — Principal investigator
First posted
Aug 1, 2022
Start date
Oct 1, 2022
Primary completion
Jun 26, 2026
Completion
Jun 26, 2026
Last update
Oct 29, 2026

Study contacts

Lisa M Wu, PhD
principal investigator · University of Aarhus

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion